Amisulpride Dosing
When augmenting clozapine with amisulpride for persistent positive symptoms in treatment-resistant schizophrenia, use 400-800 mg/day of amisulpride, while for predominant negative symptoms use low-dose amisulpride at 50-100 mg twice daily (100-200 mg/day total). 1
Context-Specific Dosing Strategies
Clozapine Augmentation for Positive Symptoms
The 2025 INTEGRATE international guidelines explicitly recommend amisulpride as one of three evidence-based options for clozapine augmentation when significant positive symptoms persist despite adequate clozapine plasma levels (350-550 ng/mL) 1. While the guidelines don't specify exact doses for augmentation, research evidence fills this gap:
- Standard augmentation dose: 400-600 mg/day
Practical approach: Start at 400 mg/day and titrate to 600-800 mg/day based on response and tolerability. Treatment duration of at least 6-12 weeks may be required to assess efficacy, as benefits may not be evident until after 6 weeks 6.
Negative Symptoms (Monotherapy or Augmentation)
For predominant negative symptoms where positive symptoms are controlled, use 50 mg twice daily (100 mg/day total). 1 This low-dose strategy is explicitly recommended in the INTEGRATE guidelines and supported by research showing efficacy at 100-300 mg/day for negative symptoms 4.
Second-Line Monotherapy
When used as second-line monotherapy after failure of a D2 partial agonist (e.g., aripiprazole, brexpiprazole):
- Acute psychotic exacerbations: 800 mg/day 4
- Predominantly positive symptoms: 400-800 mg/day 4
- Predominantly negative symptoms: 100-300 mg/day 4
Titration and Administration
Starting dose: Begin at 100 mg/day when augmenting clozapine, then up-titrate over 1 week to target dose 3. For monotherapy in acute settings, 800 mg/day can be initiated directly 4.
Dosing schedule: Amisulpride can be given once or twice daily. For augmentation, the evidence base includes both once-daily and divided dosing regimens.
Critical Safety Considerations
Cardiac Monitoring is Essential
Amisulpride augmentation significantly increases adverse events, particularly cardiac symptoms 6. When combining with clozapine:
- Monitor for QTc prolongation (both drugs carry this risk)
- Assess for orthostatic hypotension, tachycardia, palpitations
- Obtain baseline and follow-up ECGs
- Be vigilant for myocarditis symptoms (chest pain, dyspnea, fever)
Extrapyramidal Symptoms
Amisulpride augmentation increases risk of:
- Tremor
- Bradykinesia
- Akathisia 2
These are dose-related and more common at higher doses (≥400 mg/day).
Hyperprolactinemia
Expect elevated prolactin levels with amisulpride at all doses 2, 3. Monitor for galactorrhea, amenorrhea, sexual dysfunction, and long-term bone health implications.
Beneficial Side Effect: Antisialagogue Action
A unique advantage: amisulpride at 400 mg/day significantly reduces clozapine-induced hypersalivation 3. Even very low doses (50-100 mg/day) can dramatically improve both daytime and nocturnal sialorrhea 7. This dual benefit may improve adherence in patients struggling with this stigmatizing clozapine side effect.
Evidence Quality and Nuances
The INTEGRATE guidelines 1 represent the most recent (2025) and authoritative evidence, published in The Lancet Psychiatry. However, they provide limited dosing specificity for augmentation strategies. The research evidence consistently supports:
- Higher doses (400-800 mg/day) for positive symptoms and augmentation 4, 2, 5, 6
- Low doses (100-200 mg/day) for negative symptoms 1, 4, 3
Important caveat: The largest randomized controlled trial of amisulpride augmentation 6 was underpowered and failed to show statistically significant benefits, though numerical trends favored amisulpride. Benefits only emerged after 6-12 weeks, not at earlier timepoints. This suggests that adequate trial duration is critical—don't abandon the strategy prematurely.
When to Avoid or Use Cautiously
- Renal impairment: Amisulpride is renally excreted; dose reduction required
- Cardiovascular disease: Both clozapine and amisulpride carry cardiac risks
- History of seizures: Clozapine already lowers seizure threshold
- Prolactin-sensitive conditions: Avoid in prolactinomas or breast cancer
Practical Algorithm
- Ensure adequate clozapine trial first: Plasma level 350-550 ng/mL for 12 weeks 1
- If positive symptoms persist: Add amisulpride 400 mg/day, titrate to 600-800 mg/day over 1-2 weeks
- If negative symptoms predominate: Use amisulpride 50 mg twice daily (100 mg/day total)
- Monitor closely: ECG, vital signs, movement disorders, prolactin
- Allow adequate trial: Minimum 6-12 weeks before declaring treatment failure 6
- Bonus benefit: Expect improvement in clozapine-induced sialorrhea 7, 3